MedTrace Logo

Fecal Transplant for Hepatic Encephalopathy

NCT03439982 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2022-06-10

No results posted yet for this study

Summary

The purpose of the study is to determine if fecal microbiota transplant (FMT) can reverse hepatic encephalopathy (HE) in cirrhotic patients who continue to have breakthrough episodes of HE despite maintenance therapy with lactulose and/or rifaximin or metronidazole.

Conditions

  • Hepatic Encephalopathy

Interventions

BIOLOGICAL

FMT

FMT processed from routinely screened donors

Sponsors & Collaborators

  • Rebiotix Inc.

    collaborator INDUSTRY

  • University of Alberta

    lead OTHER

Principal Investigators

  • Dina Kao, MD · Associate Professor

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-12
Primary Completion
2019-08-07
Completion
2021-03-18

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03439982 on ClinicalTrials.gov